ARKG is trading 3.03% higher amid continued risk appetite for innovative healthcare and genomic stocks.
- Falling oil prices and lower Treasury yields are also supporting the move; the broader market is mixed.
- A quiet September 22, 2026 macro calendar puts emphasis on positioning and sector rotation over fresh economic data.
- ARK’s reported purchases of Beam Therapeutics, Ionis Pharmaceuticals, and Veracyte reinforce institutional interest in genomic medicine; no single dominant holding appears responsible.